ArticleScientific reports2025
Quantitative determination of Metformin in human plasma by UPLC-MS/MS and results of a 12-month pilot study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Green spectrophotometric methods for the determination of metformin-curcumin combination: ICH validation and preliminary bioanalytical applications.Scientific reports · 2026Article
- Plasma metformin concentration as a determinant of metabolic response in adults with type 1 diabetes: a 1-year prospective observational study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This pilot investigation utilized ultra-performance liquid chromatography-mass spectrometry (UPLC-MS/MS) to monitor metformin plasma concentrations in patients with type 1 diabetes. The study was conducted on a group of 11 patients. Plasma metformin was measured before treatment and at 2, 4 weeks, and 3, 6, and 12 months after initiation. Method validation was performed according to ICH M10 guidelines. The method demonstrated precision (CV < 11.07%), accuracy (89.78-99.44%), and linearity (r² > 0.98) across three independent validation runs in the 100-3000 ng/ml range. The lowest and highest measured concentrations were 163.2 and 2162.9 ng/ml, respectively, with a mean of 918 ± 616.7 ng/ml. For several patients subtherapeutic metformin levels have been reported, whereas other patients approached potentially excessive levels (> 2000 ng/ml). These findings highlight the variability in metformin exposure and the utility of UPLC-MS/MS for monitoring patient adherence and pharmacokinetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.